Phase I randomized, double-blind, placebo-controlled, single and multiple ascending dose study, to evaluate the safety and tolerability of PL-8177 administered via subcutaneous injection

Trial Profile

Phase I randomized, double-blind, placebo-controlled, single and multiple ascending dose study, to evaluate the safety and tolerability of PL-8177 administered via subcutaneous injection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs PL 8177 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 05 Feb 2018 According to a Palatin Technologies media release, first healthy subjects have been dosed in this trial and top line data is expected in the third quarter of 2018.
    • 05 Feb 2018 Status changed from planning to recruiting, according to a Palatin Technologies media release.
    • 03 Jan 2018 According to a Palatin Technologies media release, the FDA has accepted the IND application for PL-877 for ulcerative colitis. This trial is expected to begin in the current quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top